Clinical Trial Update: Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors [Phase 2]

View source ↗

Summary

Phase II study of tunlametinib in NRAS-mutant non-melanoma refractory solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Tunlametinib (tunlametinib)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Solid Cancers | Phase 2 | Status: RECRUITING